Home › Companies › JANUX THERAPEUTICS INC. › 2024-2025

JANUX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and JANUX THERAPEUTICS INC.’s Form 8-K, filed 2025-06-13 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
230Asset managers
1,811Fund votes
2025-06-11Meeting date

Proxy season: 2024-2025 2025-2026

Explore JANUX THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by JANUX THERAPEUTICS INC.

These tallies are JANUX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-13 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

JANUX THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-06-11
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: David Campbell, Ph.D.	44,740,538	--	--	9,631,829	1,866,944	Majority: yes
Elect Director: Ron Barrett, Ph.D.	44,005,362	--	--	10,367,005	1,866,944	Majority: yes
Elect Director: Winston Kung	42,187,543	--	--	12,184,824	1,866,944	Majority: yes
Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered	56,152,990	27,381	58,941	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement	53,205,989	1,150,947	15,431	--	1,866,944	Majority: yes

Source: JANUX THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-06-13 — read the filing on EDGAR.

How asset managers voted at the JANUX THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 230 asset managers that disclosed a JANUX THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of JANUX THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 53,205,989AGAINST: 1,150,947

JANUX THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 53,205,989 for, 1,150,947 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,168,490 outstanding shares: 90% for, 2% against (92% of the company cast a for/against vote).

The 228 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%

FOR: 97.9%AGAINST: 2.1%ABSTAIN: 0.0%NOT VOTED: 0.0%

Largest asset managers voting on “Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclos” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Vote
Fidelity	16,121,652	0	For
RA CAPITAL MANAGEMENT, L.P.	10,287,746	0	For
Janus Henderson	2,962,192	4,657	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,899,400	0	For
Paradigm Biocapital Advisors LP	2,554,335	0	For
T. Rowe Price	2,505,581	0	For
BlackRock	2,430,044	0	For
Vanguard	2,310,331	0	For
Woodline Partners LP	1,530,833	0	For
EcoR1 Capital, LLC	1,469,818	0	For
Logos Global Management LP	1,450,000	0	For
JANUS INVESTMENT FUND	1,328,416	0	For
State Street	1,105,629	12,510	For
Cormorant Asset Management, LP	898,076	0	For
FRANKLIN ADVISERS INC	813,175	0	For
GEODE CAPITAL MANAGEMENT, LLC	790,461	0	For
Point72	779,466	0	For
ORBIMED ADVISORS LLC	720,000	0	For
Putnam	699,296	0	For
PICTET ASSET MANAGEMENT SA	592,586	0	For
Charles Schwab	553,448	0	For
Victory Capital	466,838	0	For
Aberdeen	0	449,576	Against
Invesco	0	447,898	Against
FRANKLIN STRATEGIC SERIES	445,252	0	For

Showing the 25 largest of 228 asset managers. See all 228 in the interactive database.

2. Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 88%11%

The 220 asset managers below cast 99.9% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR: 0.6%AGAINST: 0.0%ABSTAIN: 0.1%ONE YEAR: 87.6%1 YEAR: 11.2%3 YEARS: 0.5%NOT VOTED: 0.0%1-YEAR: 0.0%THREE YEARS: 0.0%

Largest asset managers voting on “Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compens” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Fidelity	0	0	0	0	One Year
RA CAPITAL MANAGEMENT, L.P.	0	0	0	0	One Year
Janus Henderson	0	0	0	0	One Year
Paradigm Biocapital Advisors LP	0	0	0	0	One Year
T. Rowe Price	0	0	0	0	One Year
BlackRock	0	0	0	0	1 Year
Vanguard	0	0	0	0	One Year
Woodline Partners LP	0	0	0	0	One Year
EcoR1 Capital, LLC	0	0	0	0	One Year
Logos Global Management LP	0	0	0	0	One Year
JANUS INVESTMENT FUND	0	0	0	0	One Year
State Street	0	0	0	0	One Year
Cormorant Asset Management, LP	0	0	0	0	1 Year
FRANKLIN ADVISERS INC	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Point72	0	0	0	0	One Year
ORBIMED ADVISORS LLC	0	0	0	0	1 Year
Putnam	0	0	0	0	One Year
PICTET ASSET MANAGEMENT SA	0	0	0	0	One Year
Charles Schwab	0	0	0	0	1 Year
Victory Capital	0	0	0	0	One Year
Aberdeen	0	0	0	0	One Year
Invesco	0	0	0	0	One Year
FRANKLIN STRATEGIC SERIES	0	0	0	0	One Year
MPM BioImpact LLC	0	0	0	0	1 Year

Showing the 25 largest of 220 asset managers. See all 220 in the interactive database.

3. To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD 18%

FOR: 44,740,538WITHHELD: 9,631,829

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Campbell, Ph.D.”): 44,740,538 for, 9,631,829 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,168,490 outstanding shares: 76% for, 16% withheld (92% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (14,586,964 for, 0 against).

FOR 89%11%

FOR: 14,586,964 (88.8%)ABSTAIN: 1,840,349 (11.2%)

Largest asset managers voting on “To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	7,262,889	0	For
Vanguard	2,207,727	0	For
JANUS INVESTMENT FUND	0	1,328,416	Abstain
BlackRock	1,319,820	0	For
T. Rowe Price	1,066,406	0	For
FRANKLIN STRATEGIC SERIES	445,252	0	For
Putnam	333,552	0	For
Charles Schwab	276,724	0	For
State Street	258,462	337	For
Columbia Threadneedle	238,425	0	For
Aberdeen	224,788	0	For
Invesco	203,548	0	For
Victory Capital	0	180,836	Abstain
TIAA	121,036	0	For
Equitable	97,860	0	For
Bridge Builder Trust	6,132	84,722	Abstain
Delaware/Macquarie	0	76,601	Abstain
Russell Investments	60,914	0	For
QUANTITATIVE MASTER SERIES LLC	53,817	0	For
Hartford	51,244	0	For
Lincoln Financial	31,677	16,621	For
Tema ETF Trust	46,453	0	For
Northern Trust	41,496	0	For
John Hancock	24,796	11,657	For
Lord Abbett	27,953	0	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

4. To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

81% Majority: yes · of votes cast

FOR 81%WITHHELD 19%

FOR: 44,005,362WITHHELD: 10,367,005

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Barrett, Ph.D.”): 44,005,362 for, 10,367,005 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,168,490 outstanding shares: 74% for, 18% withheld (92% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (14,214,857 for, 0 against).

FOR 87%13%

FOR: 14,214,857 (86.5%)ABSTAIN: 2,212,456 (13.5%)

Largest asset managers voting on “To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	7,262,889	0	For
Vanguard	2,207,727	0	For
JANUS INVESTMENT FUND	0	1,328,416	Abstain
BlackRock	1,319,820	0	For
T. Rowe Price	1,066,406	0	For
FRANKLIN STRATEGIC SERIES	445,252	0	For
Putnam	333,552	0	For
Charles Schwab	276,724	0	For
State Street	258,462	337	For
Columbia Threadneedle	238,425	0	For
Aberdeen	0	224,788	Abstain
Invesco	203,548	0	For
Victory Capital	0	180,836	Abstain
TIAA	121,036	0	For
Equitable	57,783	40,077	For
Bridge Builder Trust	6,132	84,722	Abstain
Delaware/Macquarie	0	76,601	Abstain
Russell Investments	60,914	0	For
QUANTITATIVE MASTER SERIES LLC	53,817	0	For
Hartford	51,244	0	For
Lincoln Financial	31,677	16,621	For
Tema ETF Trust	46,453	0	For
Northern Trust	0	41,496	Abstain
John Hancock	24,796	11,657	For
Lord Abbett	0	27,953	Abstain

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

5. To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston Kung

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 42,187,543WITHHELD: 12,184,824

JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Winston Kung”): 42,187,543 for, 12,184,824 withheld, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,168,490 outstanding shares: 71% for, 21% withheld (92% of the company cast a for/withheld vote).

The 70 asset managers below cast 100% of the shares they voted on this item FOR (13,920,880 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 13,920,880 (84.7%)ABSTAIN: 2,506,433 (15.3%)

Largest asset managers voting on “To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
Fidelity	7,262,889	0	For
Vanguard	2,207,727	0	For
JANUS INVESTMENT FUND	0	1,328,416	Abstain
BlackRock	1,319,820	0	For
T. Rowe Price	1,066,406	0	For
FRANKLIN STRATEGIC SERIES	445,252	0	For
Putnam	333,552	0	For
Charles Schwab	0	276,724	Abstain
State Street	258,462	337	For
Columbia Threadneedle	238,425	0	For
Aberdeen	0	224,788	Abstain
Invesco	203,548	0	For
Victory Capital	0	180,836	Abstain
TIAA	121,036	0	For
Equitable	57,783	40,077	For
Bridge Builder Trust	6,132	84,722	Abstain
Delaware/Macquarie	0	76,601	Abstain
Russell Investments	0	60,914	Abstain
QUANTITATIVE MASTER SERIES LLC	53,817	0	For
Hartford	51,244	0	For
Lincoln Financial	31,677	16,621	For
Tema ETF Trust	46,453	0	For
Northern Trust	41,496	0	For
John Hancock	24,796	11,657	For
Lord Abbett	0	27,953	Abstain

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

6. TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 56,152,990AGAINST: 27,381

JANUX THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 56,152,990 for, 27,381 against, per its Form 8-K filed 2025-06-13 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 59,168,490 outstanding shares: 95% for, 0.1% against (95% of the company cast a for/against vote).

The 70 asset managers below cast 99.9% of the shares they voted on this item FOR (16,424,575 for, 279 against).

FOR 99.9%

FOR: 16,424,575 (100.0%)AGAINST: 279 (0.0%)ABSTAIN: 2,459 (0.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDE” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
Fidelity	7,262,889	For
Vanguard	2,207,727	For
JANUS INVESTMENT FUND	1,328,416	For
BlackRock	1,319,820	For
T. Rowe Price	1,066,406	For
FRANKLIN STRATEGIC SERIES	445,252	For
Putnam	333,552	For
Charles Schwab	276,724	For
State Street	258,799	For
Columbia Threadneedle	238,425	For
Aberdeen	224,788	For
Invesco	203,548	For
Victory Capital	180,836	For
TIAA	121,036	For
Equitable	97,860	For
Bridge Builder Trust	90,854	For
Delaware/Macquarie	76,601	For
Russell Investments	60,914	For
QUANTITATIVE MASTER SERIES LLC	53,817	For
Hartford	51,244	For
Lincoln Financial	48,298	For
Tema ETF Trust	46,453	For
Northern Trust	41,496	For
John Hancock	36,453	For
Lord Abbett	27,953	For

Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 96%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 2,899,400 (96.2%)ONE YEAR: 115,758 (3.8%)1 YEAR: 38 (0.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at JANUX THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
ADAGE CAPITAL PARTNERS GP, L.L.C.	0	0	0	0	1-Year
JPMorgan	0	0	0	0	One Year
Desjardins Global Asset Management Inc.	0	0	0	0	One Year
Coyle Financial Counsel LLC	0	0	0	0	1 Year
SIERRA SUMMIT ADVISORS LLC	0	0	0	0	1 Year

Largest JANUX THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of JANUX THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 59,168,490 shares outstanding at the time of that meeting.

Top JANUX THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Fidelity	27.25%
2	RA CAPITAL MANAGEMENT, L.P.	17.39%
3	Janus Henderson	5.01%
4	ADAGE CAPITAL PARTNERS GP, L.L.C.	4.90%
5	Paradigm Biocapital Advisors LP	4.32%
6	T. Rowe Price	4.23%
7	BlackRock	4.11%
8	Vanguard	3.90%
9	Woodline Partners LP	2.59%
10	EcoR1 Capital, LLC	2.48%

Reported JANUX THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

JANUX THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with RA Capital Healthcare Fund, L.P.	20.58%	DEF14A
RA Capital Management, L.P.	20.23%	13D
FMR (Fidelity)	15.01%	13F
FMR LLC	13.22%	DEF14A
JANUS HENDERSON GROUP PLC	7.09%	13G
Entities affiliated with Janus Henderson Group plc	6.02%	DEF14A
Entities affiliated with Paradigm BioCapital Advisors GP LLC	5.94%	DEF14A
Prosight Management, LP	5.33%	13G
Entities affiliated with Adage Capital Management, L.P.	5.17%	DEF14A
Bregua Corporation	5.07%	DEF14A

Percentages above are of 59,168,490 shares outstanding, as reported by JANUX THERAPEUTICS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from JANUX THERAPEUTICS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At JANUX THERAPEUTICS INC.'s shareholder meeting held 2025-06-11, in the 2024-2025 proxy season, 230 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,811 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers… — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: JANUX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-13.

JANUX THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.